Drug Profile
JNJ 38224342
Alternative Names: JNJ-38224342Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in Canada (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in Canada (PO, Liquid)
- 21 Jan 2010 Preclinical trials in Seasonal allergic rhinitis in USA (PO)